Home
PTGX
PTGX News

Latest Protagonist Therapeutics Inc. (PTGX) News on July 27, 2024

MT Newswires

a day ago

JPMorgan Adjusts Price Target on Protagonist Therapeutics to $48 From $39, Maintains Overweight Rating

MT Newswires

2 days ago

BTIG Raises Price Target on Protagonist Therapeutics to $51 From $41, Maintains Buy Rating

Argus Research

3 days ago

PTGX: What does Argus have to say about PTGX?

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

ACCESSWIRE

5 days ago

Protagonist Therapeutics to Participate in the BTIG Virtual Biotechnology Conference 2024

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Zacks

8 days ago

Protagonist Therapeutics (PTGX) is on the Move, Here's Why the Trend Could be Sustainable

Argus Research

10 days ago

PTGX: Raising target price to $40.00

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Investor's Business Daily

a month ago

Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600

Associated Press

a month ago

Nike, Kura Sushi fall; Infinera, Protagonist Therapeutics rise, Friday, 6/28/2024

MT Newswires

a month ago

Protagonist Therapeutics to Join S&P SmallCap 600

Protagonist Therapeutics Set to Join S&P SmallCap 600

PR Newswire

a month ago

Protagonist Therapeutics Set to Join S&P SmallCap 600

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

Insider Monkey

a month ago

Is Protagonist Therapeutics, Inc. (PTGX) a Good Healthcare Stock to Buy?

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Simply Wall St.

a month ago

We Think Some Shareholders May Hesitate To Increase Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) CEO Compensation

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

ACCESSWIRE

a month ago

Protagonist Reports Updated Long Term Results from Rusfertide Phase 2 REVIVE Study at the EHA2024 Congress Showing Durable Hematocrit Control

MT Newswires

a month ago

Protagonist Therapeutics Insider Sold Shares Worth $1,231,650, According to a Recent SEC Filing

MT Newswires

a month ago

Protagonist Therapeutics Insider Sold Shares Worth $280,000, According to a Recent SEC Filing

Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Simply Wall St.

2 months ago

Has Protagonist Therapeutics, Inc.'s (NASDAQ:PTGX) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

ACCESSWIRE

2 months ago

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

ACCESSWIRE

2 months ago

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations

GuruFocus.com

3 months ago

Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations

Associated Press Finance

3 months ago

Protagonist Therapeutics: Q1 Earnings Snapshot

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

ACCESSWIRE

3 months ago

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

ACCESSWIRE

3 months ago

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Simply Wall St.

3 months ago

We Might See A Profit From Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Soon

Turnstone Biologics Appoints William Waddill to its Board of Directors

GlobeNewswire

3 months ago

Turnstone Biologics Appoints William Waddill to its Board of Directors

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

Zacks

4 months ago

All You Need to Know About Protagonist Therapeutics (PTGX) Rating Upgrade to Buy

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

GuruFocus.com

4 months ago

Protagonist Therapeutics Inc CEO Sells 25,000 Shares

Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%

Simply Wall St.

4 months ago

Shareholders have faith in loss-making Protagonist Therapeutics (NASDAQ:PTGX) as stock climbs 3.7% in past week, taking five-year gain to 135%

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

ACCESSWIRE

4 months ago

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet

Zacks

4 months ago

Wall Street Analysts Think Protagonist Therapeutics (PTGX) Could Surge 48.38%: Read This Before Placing a Bet

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

ACCESSWIRE

4 months ago

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

ACCESSWIRE

5 months ago

Late-Breaking Presentation at American Academy of Dermatology 2024 Annual Meeting Shows that JNJ-2113, the First and Only Investigational Targeted Oral Peptide, Maintained Skin Clearance in Moderate-To-Severe Plaque Psoriasis Through One Year

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

ACCESSWIRE

5 months ago

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

Zacks

5 months ago

Zacks.com featured highlights Protagonist Therapeutics, AxoGen, Western Digital and Phunware

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Simply Wall St.

5 months ago

This Just In: Analysts Are Boosting Their Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Outlook for This Year

Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.

5 months ago

Earnings Update: Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Just Reported And Analysts Are Boosting Their Estimates

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?

Zacks

5 months ago

Earnings Estimates Moving Higher for Protagonist Therapeutics (PTGX): Time to Buy?

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice

Zacks

5 months ago

Are You Looking for a Top Momentum Pick? Why Protagonist Therapeutics (PTGX) is a Great Choice

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

Zacks

5 months ago

Protagonist Therapeutics (PTGX) Upgraded to Buy: What Does It Mean for the Stock?

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade

Zacks

5 months ago

Wall Street Analysts Believe Protagonist Therapeutics (PTGX) Could Rally 37.16%: Here's is How to Trade

Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why

Zacks

5 months ago

Recent Price Trend in Protagonist Therapeutics (PTGX) is Your Friend, Here's Why

Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations

Simply Wall St.

5 months ago

Protagonist Therapeutics Full Year 2023 Earnings: Beats Expectations

We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn

Simply Wall St.

5 months ago

We're Not Worried About Protagonist Therapeutics' (NASDAQ:PTGX) Cash Burn

Associated Press Finance

5 months ago

Protagonist Therapeutics: Q4 Earnings Snapshot

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

ACCESSWIRE

5 months ago

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

ACCESSWIRE

5 months ago

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

Protagonist Therapeutics Reports Granting of Inducement Awards

ACCESSWIRE

5 months ago

Protagonist Therapeutics Reports Granting of Inducement Awards

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

GuruFocus.com

5 months ago

Steven Cohen Adjusts Position in Protagonist Therapeutics Inc

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

ACCESSWIRE

6 months ago

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Zacks

6 months ago

Protagonist (PTGX) Up 14% on Licensing Deal With Takeda

Exxon, Chevron show production strength despite sector woes

Yahoo Finance Video

6 months ago

Exxon, Chevron show production strength despite sector woes

SkyWest Inc (SKYW) Reports Q4 and Full-Year 2023 Earnings, Reveals Increased Revenue and Net Income

GuruFocus.com

6 months ago

SkyWest Inc (SKYW) Reports Q4 and Full-Year 2023 Earnings, Reveals Increased Revenue and Net Income

Takeda pays $300M to license Protagonist drug for blood disorder

BioPharma Dive

6 months ago

Takeda pays $300M to license Protagonist drug for blood disorder

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

ACCESSWIRE

6 months ago

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

12 Stocks with Potential to Explode

Insider Monkey

6 months ago

12 Stocks with Potential to Explode

Customers Bancorp, Inc. Declares Quarterly Cash Dividend on Its Series E and Series F Preferred Stock

Business Wire

6 months ago

Customers Bancorp, Inc. Declares Quarterly Cash Dividend on Its Series E and Series F Preferred Stock

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

ACCESSWIRE

6 months ago

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

GuruFocus.com

6 months ago

Chief Business Officer Jonathan Mcneill Sells 20,000 Shares of Dyne Therapeutics Inc (DYN)

Delek US Holdings to Host Fourth Quarter 2023 Conference Call on February 27th

PR Newswire

6 months ago

Delek US Holdings to Host Fourth Quarter 2023 Conference Call on February 27th

Morningstar Research

6 months ago

Analyst Report: Xerox Holdings Corporation

Xerox Stock Surges as CEO Says Future Is Ripe With Opportunities

Barrons.com

6 months ago

Xerox Stock Surges as CEO Says Future Is Ripe With Opportunities

Tesla, Boeing downgraded: Wall Street's top analyst calls

The Fly

6 months ago

Tesla, Boeing downgraded: Wall Street's top analyst calls

Xerox Releases Fourth-Quarter and Full-Year Results

Business Wire

6 months ago

Xerox Releases Fourth-Quarter and Full-Year Results

The lasting impacts of Boeing 737 groundings on airlines

Yahoo Finance Video

6 months ago

The lasting impacts of Boeing 737 groundings on airlines

Is Spirit Airlines Stock a Buy?

Motley Fool

6 months ago

Is Spirit Airlines Stock a Buy?

Northwest Bancshares Inc Reports Mixed Q4 Results Amid Interest Rate and Liquidity Challenges

GuruFocus.com

6 months ago

Northwest Bancshares Inc Reports Mixed Q4 Results Amid Interest Rate and Liquidity Challenges

Associated Press Finance

6 months ago

Northwest Bancshares: Q4 Earnings Snapshot

Northwest Bancshares, Inc. Announces Fourth Quarter 2023 Earnings and Quarterly Dividend

PR Newswire

6 months ago

Northwest Bancshares, Inc. Announces Fourth Quarter 2023 Earnings and Quarterly Dividend

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Business Wire

6 months ago

Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer

Rover Announces Expiration of Hart-Scott-Rodino Waiting Period

GlobeNewswire

6 months ago

Rover Announces Expiration of Hart-Scott-Rodino Waiting Period

Lakeland Financial (NASDAQ:LKFN) Is Paying Out A Larger Dividend Than Last Year

Simply Wall St.

6 months ago

Lakeland Financial (NASDAQ:LKFN) Is Paying Out A Larger Dividend Than Last Year

Patrick (PATK) to Buy Sportech, Expand Outdoor Enthusiast Space

Zacks

6 months ago

Patrick (PATK) to Buy Sportech, Expand Outdoor Enthusiast Space

Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX)

GuruFocus.com

6 months ago

Insider Suneel Gupta Sells 5,000 Shares of Protagonist Therapeutics Inc (PTGX)

Walgreens, Eli Lilly, Crypto CEOs and more: C-Suite Insights

Yahoo Finance Video

6 months ago

Walgreens, Eli Lilly, Crypto CEOs and more: C-Suite Insights

Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know

Zacks

6 months ago

Wall Street Analysts Predict a 105.85% Upside in NovoCure (NVCR): Here's What You Should Know

Privia Health Group, Inc. (NASDAQ:PRVA) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?

Simply Wall St.

6 months ago

Privia Health Group, Inc. (NASDAQ:PRVA) Is Up But Financials Look Inconsistent: Which Way Is The Stock Headed?

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

ACCESSWIRE

7 months ago

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

Simply Wall St.

7 months ago

A Look At The Fair Value Of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

5 Industrial Stocks Rising More Than 40% YTD With Room to Run

Zacks

7 months ago

5 Industrial Stocks Rising More Than 40% YTD With Room to Run

Don't Race Out To Buy John Wiley & Sons, Inc. (NYSE:WLY) Just Because It's Going Ex-Dividend

Simply Wall St.

7 months ago

Don't Race Out To Buy John Wiley & Sons, Inc. (NYSE:WLY) Just Because It's Going Ex-Dividend

Golar LNG (GLNG) Up 4.6% Since Last Earnings Report: Can It Continue?

Zacks

7 months ago

Golar LNG (GLNG) Up 4.6% Since Last Earnings Report: Can It Continue?

Petrobras (PBR) Considers Increasing Stake in Braskem to Aid Sale

Zacks

7 months ago

Petrobras (PBR) Considers Increasing Stake in Braskem to Aid Sale

Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...

GuruFocus.com

7 months ago

Insider Sell Alert: CEO PATEL DINESH V PH D Sells 75,000 Shares of Protagonist Therapeutics Inc ...

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

GlobeNewswire

7 months ago

Paratek Pharmaceuticals Announces Inclusion of Oral NUZYRA® in China’s National Reimbursement Drug List

Reuters

7 months ago

UPDATE 2-Brazil senators to probe petrochemical Braskem's sinking ground havoc

Reuters

7 months ago

Brazil senators to probe petrochemical Braskem's sinking ground havoc

Reuters

7 months ago

Moody's downgrades Brazil's Braskem on potential extra damages provisions

Reuters

8 months ago

UPDATE 1-City hall in Brazil's Maceio requests new damages deal with Braskem

The Buckle, Inc. Announces a $2.50 Per Share Special Cash Dividend, a $0.35 Per Share Quarterly Dividend, and Leadership Appointments

Business Wire

8 months ago

The Buckle, Inc. Announces a $2.50 Per Share Special Cash Dividend, a $0.35 Per Share Quarterly Dividend, and Leadership Appointments

Are Retail-Wholesale Stocks Lagging ACV Auctions (ACVA) This Year?

Zacks

8 months ago

Are Retail-Wholesale Stocks Lagging ACV Auctions (ACVA) This Year?

Borr Drilling Limited (NYSE:BORR) Q3 2023 Earnings Call Transcript

Insider Monkey

8 months ago

Borr Drilling Limited (NYSE:BORR) Q3 2023 Earnings Call Transcript

PR Newswire

8 months ago

Borr Drilling Limited - Grant of Restricted Stock Units and Share Options

Is Weakness In Cavco Industries, Inc. (NASDAQ:CVCO) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Simply Wall St.

9 months ago

Is Weakness In Cavco Industries, Inc. (NASDAQ:CVCO) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects?

Payoneer Reports Third Quarter 2023 Financial Results

Business Wire

9 months ago

Payoneer Reports Third Quarter 2023 Financial Results

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Business Wire

9 months ago

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

Share on Social Networks: